Fig. 1: hSBA GMTs before and after primary dose of either MenACYW-TT or MCV4-CRM, and before and after MenACYW-TT booster. | Pediatric Research

Fig. 1: hSBA GMTs before and after primary dose of either MenACYW-TT or MCV4-CRM, and before and after MenACYW-TT booster.

From: Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10–12 years: phase III randomized trial complementary analysis of immune persistence 3–6 years after priming

Fig. 1

Persistence of hSBA GMTs to serogroup A (a), serogroup C (b), serogroup W (c) and serogroup Y (d) following priming vaccination with MenACYW-TT or MCV4-CRM. MenACYW-TT primed (pooled groups 1, 3 & 4) consists of participants who were MenACYW-TT primed in the previous studies (MET50 or MET43); MenACYW-CRM primed (Group 2) consists of participants who were MCV4-CRM primed in the previous study (MET50). The pre-priming dose GMTs were measured on D0 of studies MET50 and MET43; the post-priming dose GMTs were measured 30 days after administration of the priming vaccine in studies MET43 and MET50. Error bars display the 95% confidence intervals. CI confidence interval, D day, GMT geometric mean titer, hSBA serum bactericidal antibody assay using human complement, n total number of participants.

Back to article page